Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:42:09.310Z.
Calculation as of: 2026-10-06T13:42:09.310Z.
Quote observation: 2026-10-06T13:40:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 304a80059de762086f201eae28471a3f317e523c87af6f00839e9007cc2266bd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Precision BioSciences, Inc.
Market Cap
$173.34M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$171.61M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$169.95M
EV/EBITDA Ratio
N/A
TTM Avg
8.39x
3Y Avg
66.32x
5Y Avg
66.32x
Market Cap
$178.54M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.71M
EV/EBITDA Ratio
145.49x
TTM Avg
155.63x
3Y Avg
70.41x
5Y Avg
70.41x
Market Cap
$158.25M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$155.04M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $173.34M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $171.61M | N/A | N/A | N/A | N/A |
| Coherus Oncology, Inc. (CHRS)vs › | $169.95M | N/A | 8.39x | 66.32x | 66.32x |
| Cue Biopharma, Inc. (CUE)vs › | $177.29M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $178.54M | N/A | N/A | N/A | N/A |
| Journey Medical Corporation (DERM)vs › | $183.71M | 145.49x | 155.63x | 70.41x | 70.41x |
| Inogen, Inc. (INGN)vs › | $161.12M | N/A | 29.09x | 58.55x | 59.27x |
| ALX Oncology Holdings Inc. (ALXO)vs › | $158.25M | N/A | N/A | N/A | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $155.04M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $154.76M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
